- Report
- March 2024
- 186 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Report
- May 2024
- 183 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- April 2024
- 137 Pages
Global
From €3746EUR$3,899USD£3,203GBP
- Report
- October 2023
- 157 Pages
Global
From €2402EUR$2,500USD£2,054GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2883EUR$3,000USD£2,464GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- March 2024
- 267 Pages
Global
From €7639EUR$7,950USD£6,531GBP
- Report
- September 2023
- 180 Pages
Global
From €5285EUR$5,500USD£4,518GBP
- Report
- November 2023
- 182 Pages
Global
From €4708EUR$4,900USD£4,025GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,027GBP
- Report
- February 2021
- 120 Pages
Global
From €5717EUR$5,950USD£4,888GBP
- Report
- November 2022
- 63 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- September 2019
- 71 Pages
Global
From €4756EUR$4,950USD£4,066GBP
- Report
- April 2020
- 139 Pages
North America
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- April 2020
- 154 Pages
Europe
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- April 2020
- 147 Pages
Asia Pacific
From €2018EUR$2,100USD£1,725GBP
€2883EUR$3,000USD£2,464GBP
- Report
- January 2022
- 110 Pages
Global
From €4564EUR$4,750USD£3,902GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Drug Pipelines
- September 2022
- 30 Pages
Global
From €2642EUR$2,750USD£2,259GBP
- Report
- August 2022
- 30 Pages
Global
From €3123EUR$3,250USD£2,670GBP
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder that affects the motor neurons in the brain and spinal cord. As a result, patients experience muscle weakness, paralysis, and eventually death. The ALS drug market is a subset of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological disorders such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The ALS drug market is relatively small compared to other CNS drug markets, but it is growing due to increased awareness and research into the disease.
The ALS drug market is composed of both generic and branded drugs. Generic drugs are typically used to treat the symptoms of ALS, while branded drugs are used to slow the progression of the disease. Currently, there are several companies that are actively researching and developing new treatments for ALS, including Biogen, Novartis, and Sanofi. Additionally, there are several companies that are focused on providing generic drugs to treat the symptoms of ALS, such as Mylan and Teva Pharmaceuticals. Show Less Read more